Regulon 0.15mg/0.03mg 63 tablets — Made in Hungary — Free Delivery

(Regulon )
Regulon 0.15mg/0.03mg 63 tablets — Made in Hungary — Free Delivery
Availability: In Stock

Product description

Regulon® tablets are used for oral contraception. Before prescribing Regulon®, the woman's individual risk factors should be assessed, especially those related to the risk of venous thromboembolism (VTE), and the risk of venous thromboembolic complications should be compared when taking Regulon® with the risk when taking other combined hormonal contraceptives (KGC).


One film-coated tablet contains (active ingredients):
  • desogestrel - 0.15 mg;
  • ethinylestradiol - 0.03 mg.
Excipients: alpha-tocopherol (all-rac-α-tocopherol), magnesium stearate, colloidal anhydrous silicon dioxide, stearic acid, povidone, potato starch, lactose monohydrate; shell composition: propylene glycol, macrogol 6000, hypromellose.


Combined hormonal contraceptives (CHCs) should not be used for the conditions listed below. If this condition occurs for the first time while taking CHC, its use should be stopped immediately.
Established pregnancy or possible pregnancy.
The presence or risk of venous thromboembolism (VTE):
  • current venous thromboembolism, in particular due to anticoagulant therapy or a history of (eg deep vein thrombosis (DVT) or pulmonary embolism (PE));
  • known hereditary or acquired tendency to venous thromboembolism, such as resistance to activated protein C (including factor V Leiden mutation), antithrombin III deficiency, protein C deficiency, protein S deficiency;
  • major surgery with prolonged immobilization;
  • high risk of venous thromboembolism due to the presence of multiple risk factors.
Presence or risk of developing arterial thromboembolism (ATE):
  • current or history of arterial thromboembolism (eg myocardial infarction) or a prodromal condition (eg angina pectoris);
  • cerebrovascular disease - current or history of stroke, or prodromal condition (for example, transient ischemic attack (TIA));
  • an established hereditary or acquired tendency to arterial thromboembolism, such as hyperhomocysteinemia and the presence of antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant);
  • a history of migraine with focal neurological symptoms;
  • high risk of developing ATE due to the presence of multiple risk factors or the presence of one of the following serious risk factors:
  • diabetes mellitus with vascular complications;
  • severe arterial hypertension;
  • severe dyslipoproteinemia.
Current or history of pancreatitis associated with severe hypertriglyceridemia.
Have a history of severe liver disease or a history of severe liver disease until liver function tests return to normal.
Current or history of liver tumors (benign or malignant).
Known or suspected malignant tumors (eg genitals or mammary glands) that are sex hormone dependent.
Endometrial hyperplasia.
Vaginal bleeding of unknown etiology.
Hypersensitivity to active ingredients or to any of the excipients of the preparation.
Regulon® is contraindicated for simultaneous use with preparations containing ombitasvir / paritaprevir / ritonavir and dasabuvir.

Mode of application

Start taking pills from the first day of the menstrual cycle and take one pill per day for 21 days without interruption, if possible - at the same time of day. Then a 7-day break should be taken, during which withdrawal bleeding occurs. The next day after a 7-day break (4 weeks after taking the first tablet, on the same day of the week), the preparation is resumed from the next blister pack, which also contains 21 tablets, even if the bleeding has not stopped. This regimen should be followed as long as there is a need for contraception. If the doctor's instructions are followed, the contraceptive effect persists for the 7-day break in taking the pills.
The tablets are taken orally in the order indicated on the blister pack.

Application features

The safety and effectiveness of desogestrel in adolescents under the age of 18 has not been established. No data.
The influence of CPC on the ability to drive vehicles or other mechanisms has not been identified.


There have been no reported serious adverse reactions resulting from an overdose of oral contraceptives. Possible symptoms in this case include: nausea, vomiting, and minor vaginal bleeding in young girls. Thus, an overdose of the preparation does not require treatment. However, if an overdose is detected within 2-3 hours or when taking a large number of tablets, gastric lavage can be performed. There is no specific antidote, symptomatic therapy should be carried out.

Side effects

Mental disorders: often (≥ 1/100 - <1/10) - depressed mood, mood changes.
Nervous system disorders: often (≥ 1/100 - <1/10) - headache.
Disorders of the gastrointestinal tract: often (≥ 1/100 - <1/10) - nausea, abdominal pain.
Disorders of the reproductive system and mammary glands: often (≥ 1/100 - <1/10) - breast tenderness, pain in the mammary glands.

Storage conditions

Store at a temperature not exceeding 30 ° C, out of the reach of children.
Shelf life is 3 years.

Tags: Regulon

There are no reviews for this product.

Write a review

Buyers Online